

Filed: October 7, 2019

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
SAWAI USA, INC., AND
SAWAI PHARMACEUTICAL CO., LTD.,

Petitioner,

v.

BIOGEN MA INC.,

Patent Owner.

Case No. IPR2018-0143¹
U.S. Patent No. 8,399,514

**PETITIONER'S REPLY TO BIOGEN'S
PATENT OWNER RESPONSE**

¹ Case IPR2019-00789 has been joined with this proceeding.

TABLE OF CONTENTS

	Page
INTRODUCTION	1
I. The Claims of the '514 Patent Were Obvious	2
A. POSAs Were Motivated to Optimize the DMF Daily Dose.....	2
B. POSAs Would Have Reasonably Expected 480 mg/day to Be Efficacious.....	4
1. Schimrigk Demonstrated 360 mg/day and 720 mg/day Were Efficacious	4
2. The January 2006 Press Release Confirmed Successful RRMS Treatment with DMF Monotherapy.....	6
3. DMF's Use to Treat Psoriasis Supports Obviousness.....	7
4. Kappos 2006 Abstract Confirmed that 360 mg/day and 720 mg/day Were Efficacious	7
5. The Kappos Presentation Provided More Confirmation That 360 mg/day Was Efficacious.....	8
6. Petitioner Has Not Relied on Fox/Gold or the EMA to support its Prima Facie Case	10
7. POSAs Would Not Have Looked to Doses Higher Than 720 mg/day	10
8. WO '342 Provides Additional Confirmatory Evidence of a Reasonable Expectation of Success	11
9. The Ground 4 References Likewise Provide a Reasonable Expectation of Success.....	12
C. All Dependent Claims Are Obvious	12
D. Biogen's Secondary Considerations Fail to Overcome the Prima Facie Case.....	12
1. Biogen Has Not Established Unexpected Results	12
2. Biogen Has Not Established Commercial Success	13

TABLE OF CONTENTS
(continued)

	Page
3. Biogen Has Not Established Long-Felt Need or Praise of Others.....	14
II. Petitioner’s Grounds Rely Exclusively on Prior Art.....	15
A. Petitioner’s Ground 1 Relies on § 102(b) Prior Art.....	15
B. The Kappos Trial Was Not Solely Dr. O’Neill’s Work	16
C. Petitioner Did Not Raise a Priority Date Challenge in this IPR.....	22
D. Biogen’s Own Press Releases are Prior Art.....	23

..

TABLE OF AUTHORITIES

Page

CASES

<i>Acceleration Bay, LLC v. Activision Blizzard Inc.</i> , 908 F.3d 765 (Fed. Cir. 2018)	24
<i>Acorda Therapeutics, Inc. v. Roxane Labs., Inc.</i> , 903 F.3d 1310 (Fed. Cir. 2018)	13
<i>Allergan, Inc. v. Apotex Inc.</i> , 754 F.3d 952 (Fed. Cir. 2014)	16
<i>Biogen Int’l GmbH v. Mylan Pharm., Inc.</i> , No. 17-cv-116-IMK (N.D.W. Va.)	21
<i>Biogen MA Inc. v. Forward Pharma A/S</i> , Interference 106,023 (PTAB Mar. 31, 2017) (Paper 813)	11
<i>Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc.</i> , IPR2015-01850, 2017 WL 950736 (PTAB Mar. 9, 2017).....	18
<i>Coriant (USA) Inc. v. Oyster Optics, LLC</i> , IPR2018-00258, 2018 WL 2761411 (PTAB June 6, 2018)	24
<i>E.I. Dupont de Nemours & Co. v. Synvina C.V.</i> , 904 F.3d 996 (Fed. Cir. 2018)	2, 7
<i>EmeraChem Holdings, LLC v. Volkswagen Group of Am., Inc.</i> , 859 F.3d 1341 (Fed. Cir. 2017)	22
<i>Ex Parte ePlus, Inc.</i> , No. 2010-00784, 2011 WL 1918594 (BPAI May 18, 2011), <i>aff’d per curiam, In re ePlus, Inc.</i> , 540 F. App’x 998 (Fed. Cir. 2013)	24, 25
<i>Fisher & Paykel Healthcare Ltd. v. ResMed Ltd.</i> , IPR2017-00062, 2018 WL 1605264.....	25
<i>FWP IP APS v. Biogen MA, Inc.</i> , 749 F. App’x 969 (Fed. Cir. 2018)	11

...

TABLE OF AUTHORITIES
(continued)

	Page
<i>Haliburton Energy Servs., Inc. v. Dynamic 3D Geosolutions LLC</i> , IPR2014-01186, slip op. (PTAB Feb. 18, 2015)	24
<i>In re Cronyn</i> , 890 F.2d 1158 (Fed. Cir. 1989)	24
<i>In re Katz</i> , 687 F.2d 450 (C.C.P.A. 1982)	17
<i>In re Morsa</i> , 713 F.3d 104 (Fed. Cir. 2013)	23
<i>Intel Corp. v. Alacritech, Inc.</i> , IPR2017-01392, 2018 WL 6190430 (PTAB Nov. 26, 2018).....	25
<i>Johns Manville Corp. v. Knauf Insulation, Inc.</i> , IPR2015-01453, 2017 WL 378547 (PTAB Jan. 11, 2017), <i>aff'd</i> , 730 F. App'x 934 (Fed. Cir. 2018)	23
<i>Liberty Mutual Ins., Co. v. Progressive Casualty Ins. Co.</i> , CBM2012-00010, 2013 WL 6665065 (PTAB Feb. 25, 2013).....	23
<i>Mako Surgical Corp. v. Blue Belt Techs., Inc.</i> , IPR2015-00630, 2016 WL 5098789 (PTAB Aug. 1, 2016).....	22
<i>Merck & Co. v. Teva Pharm. USA, Inc.</i> , 395 F.3d 1364 (Fed. Cir. 2005)	13
<i>SRI Int'l, Inc. v. Internet Sec. Sys., Inc.</i> , 511 F.3d 1186 (Fed. Cir. 2008)	24
<i>Stored Value Solutions, Inc. v. Card Activation Techs., Inc.</i> , 499 F. App'x 5 (Fed. Cir. 2012)	23, 24
<i>Teva Pharm. USA, Inc. v. Sandoz, Inc.</i> , 789 F.3d 1335 (Fed. Cir. 2015)	14
<i>Varian Med. Sys., Inc. v. William Beaumont Hosp.</i> , IPR2016-00163, 2017 WL 2117016 (PTAB May 4, 2017).....	17

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.